Estrella Immunopharma, Inc. Share Price & Technical Analysis
ESLA · $1.12 (-3.45%)
Healthcare / Biotechnology
$1.12
-3.45%
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukem…
Price chart
Seasonality
May has 0 positive and 3 negative years (last 5 years shown)
-25% return in May, -9% avg return in past 3 year May month.
9% return in 2026, -16% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -27% | 9% | -8% | 60% | -25% | – | – | – | – | – | – | – | 9% |
| 25 | -17% | 0% | -10% | 22% | -9% | 0% | -11% | 25% | 0% | 100% | -12% | -27% | 61% |
| 24 | -8% | -9% | 20% | -23% | -18% | 11% | 60% | -24% | 0% | -27% | 38% | 0% | 19% |
| 23 | 4% | 1% | -1% | 1% | 0% | 1% | -7% | -39% | 11% | -69% | 6% | -35% | -128% |
| 22 | 0% | 0% | 1% | 0% | 0% | 0% | 1% | 0% | 0% | 0% | 3% | -1% | 4% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Weak
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It offers ARTEMIS, a cell receptor platform to develop and commercialize T-cell therapies targeting CD19 and CD22 for the treatment of hematologic malignancies. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California. Estrella Immunopharma, Inc. is a subsidiary of Eureka Therapeutics, Inc.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$52.48M
P/E ratio
—
52W high
$3.15
52W low
$0.78
Volume
51,502
Beta
0.98
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Estrella Immunopharma, Inc. share price today?
- Estrella Immunopharma, Inc. (ESLA) last traded around $1.12 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does ESLA have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for ESLA. Download the app for real-time alerts.
- How can I analyze Estrella Immunopharma, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.